Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
AMG 706 is a multikinase inhibitor that predominantly targets receptor tyrosine kinases, including VEGFR1, VEGFR2, VEGFR3, c-Kit, PDGFR, and RET (IC50s = 2, 3, 6, 8, 84, and 59 nM, respectively).1 It also potently inhibits CSF1R and ZAK (IC50s = 5.6 and 8 nM, respectively), as well as several mutants of c-Kit.2 AMG 706 inhibits the proliferation of human endothelial cells induced by VEGF but not FGF.1 Oral administration of AMG 706 blocks VEGF-induced angiogenesis in the rat corneal model and induces regression of established A431 xenografts in mice.1
WARNING This product is not for human or veterinary use.
1. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-
2. Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29(11), 1046-1051 (2011).